Pier 70 Ventures

Pier 70 Ventures is a venture capital investment firm based in Seattle, Washington, founded in 2021. The firm focuses on funding disruptive technologies within the healthcare sector that have the potential to transform existing practices and improve outcomes. Pier 70 Ventures targets companies at various stages of development, including seed-stage, early-stage, and later-stage businesses, emphasizing innovation and significant impact within the healthcare industry.

Miller Adams JD

Co-Founder and Managing Partner

Robert Balk

Co-Founder and Venture Partner

Shaun Hawkins

Managing Partner

Preetha Ram Ph.D

Managing Partner

6 past transactions

Flyte

Seed Round in 2024
Pelvital USA, Inc. is a privately held company based in Minneapolis, Minnesota, focused on restoring pelvic health and enhancing the quality of life for individuals suffering from pelvic floor disorders. Founded in 2016, the company is currently evaluating the Flyte system, an investigational medical device designed to strengthen and potentially heal the pelvic floor muscle system. This device employs a unique mechanotherapy technology, which has been shown to effectively heal and strengthen muscle systems. Through its innovative approach, Pelvital aims to provide significant improvements for patients dealing with pelvic floor issues.

PrīmSphera

Seed Round in 2023
PrīmSphera is a sensor‑technology company that develops contactless monitoring solutions based on radio‑frequency polarization mode dispersion. The firm’s flagship product is a connected platform for hospital‑at‑home care, using a non‑contact device to track fluid changes and provide early, actionable data to patients and clinicians. In addition, its sensor fusion technology measures heart rate and respiratory rate without touching the patient, enabling value‑based care and encouraging early intervention. Originally founded to commercialize research by Dr. Thomas Pratt at the University of Notre Dame, PrīmSphera targets healthcare as its primary market while also exploring applications in defense and food processing.

KayoThera

Series A in 2023
KayoThera is a biotechnology company developing therapeutics for late-stage and metastatic cancers. Its programs inhibit a key enzyme protecting cancer cells and deplete regulatory T-cells, aiming to cure previously incurable cancers.

Community

Venture Round in 2023
Community is a messaging and engagement platform that enables two-way, direct communication between influencers, brands, public figures, creators, artists, and their audiences at scale. The platform connects businesses and organizations with consumers through a secure channel, including a unique 10-digit phone number, and aims to facilitate authentic interactions while addressing data privacy concerns and reducing the toxicity often associated with traditional social media.

ZeroCarb LYFE

Venture Round in 2023
ZeroCarbLYFE is a food tech company with the mission to bring joy into healthy food. We invented multiple high proteins, and low/no carb foods that taste as good as or better than carb-loaded alternatives.

DocSpera

Series B in 2022
DocSpera is an integrated surgical coordination platform that enhances synchronization across multiple sites and teams, ultimately improving workflow efficiencies and patient care. The company's proprietary platform automates pre-surgical coordination and facilitates real-time, secure synchronization of cases and images among key stakeholders, including surgeons, care teams, and device suppliers, utilizing electronic health record data. Additionally, DocSpera's intelligent surgical planning capabilities allow for continuous patient monitoring from the surgical decision phase through recovery, providing real-time insights and operating room dashboards to support physicians in their decision-making processes. Headquartered in Sunnyvale, California, DocSpera operates under Compliant Innovations Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.